April 25, 2024
Parexel and Palantir Expand Collaboration to Accelerate Clinical Data Delivery and Power Clinical Outcomes for Patients
Parexel and Palantir announced a multi-year strategic partnership to leverage artificial intelligence to help enhance and accelerate the delivery of safe and effective clinical trials for the world’s biopharmaceutical customers.
April 4, 2024
Parexel Named “Best Contract Research Organization” at 17th Annual Vaccine Industry Excellence (ViE) Awards
Company recognized by a distinguished industry advisory board for its expertise and leadership in supporting the development of vaccines
March 18, 2024
Parexel Announces CEO Succession Plan
Chief Operating & Growth Officer Peyton Howell to succeed Jamie Macdonald effective May 15, 2024; Mr. Macdonald to retire as CEO and continue on the Board of Directors through Dec. 31, 2024
February 1, 2024
Parexel Appoints Susan R. Salka to Board of Directors
Ms. Salka brings more than 30 years of healthcare leadership and staffing expertise, including strong C-suite, financial and ESG expertise to advance the company’s Patients-first focus and growth initiatives.
January 10, 2024
Parexel and Japanese Foundation for Cancer Research Announce Strategic Alliance
Collaboration streamlines patient access to oncology clinical trials further expands Parexel's Site Alliance Network across Asia/Pacific